) --




) hit a new 52-week high Wednesday as it is currently trading at $94.08, above its previous 52-week high of $93.16 with 334,945 shares traded as of 10:02 a.m. ET. Average volume has been 499,500 shares over the past 30 days.

Shire has a market cap of $17.4 billion and is part of the

health care

sector and


industry. Shares are up 28.4% year to date as of the close of trading on Tuesday.

Shire plc, together with subsidiaries, engages in the research, development, manufacture, sale, and distribution of pharmaceutical products. The company operates through two segments: Specialty Pharmaceuticals and Human Genetic Therapies. The company has a P/E ratio of 29.3, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 16.7.

  • Practice your SHPGY trading strategies and win cash in our stock game.

TheStreet Ratings rates Shire as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full

Shire Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center